The Effect of Pregabalin on Chemokines in Patients with Neuropathic Pain

Abstract

We attempt to discuss the effect of pregabalin on chemokines and clinical efficacy in neuropathic pain patients. We selected 40 patients with neuropathic pain from December 2018 to December 2020 as research objects and divided them into two groups, one is observation group (20 cases) and the other is control group (20 cases) randomly. Treated observation group with pregabalin and treated control group with gabapentin. Extracted cerebrospinal fluid from the patients and detected its concentration levels of C-X3-C motif chemokine ligand 1, C-X-C motif chemokine ligand 1, C-X-C motif chemokine ligand 8 and C-C motif chemokine ligand 2 of both groups, compared the concentration levels, the adverse drug reactions and clinical effects of both groups. After treatment, the concentration levels of cerebrospinal fluid chemokines C-X3-C motif chemokine ligand 1, C-X-C motif chemokine ligand 1, C-X-C motif chemokine ligand 8 and C-C motif chemokine ligand 2 decreased in both groups. Contrast control groups, observation group decreased more obvious (p<0.05) and observation group had higher clinical remission rate than the other (p<0.05), both of which had statistical significance. For patients with neuropathic pain, pregabalin treatment can reduce the chemokines in cerebrospinal fluid of patients and significantly relieve patient’s pain.